ARCUTIS BIOTHERAPEUTICS INC
NASDAQ: ARQT (Arcutis Biotherapeutics, Inc.)
Last update: 13 hours ago32.07
0.10 (0.31%)
| Previous Close | 31.97 |
| Volume | 1,882,616 |
| Price / Earnings (Forward) | 31.87 |
| Price / Sales | 8.94 |
| Price / Book | 17.91 |
| 52 Weeks Range |
| Profit Margin | -60.95% |
| Operating Margin (TTM) | -37.25% |
| Diluted EPS (TTM) | -1.04 |
| Quarterly Revenue Growth (YOY) | 32.80% |
| Total Debt/Equity (MRQ) | 77.67% |
| Current Ratio (MRQ) | 3.55 |
| Operating Cash Flow (TTM) | -110.94 M |
| Levered Free Cash Flow (TTM) | -66.54 M |
| Return on Assets (TTM) | -18.43% |
| Return on Equity (TTM) | -70.57% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Arcutis Biotherapeutics, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | 1.0 |
| Price Volatility | -3.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 4.0 |
| Relative Valuation | NA |
| Financial Health | -0.9 |
| Macro Environment | -0.3 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | -0.18 |
Select this tab to load the latest available analysis.
|
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.95% |
| % Held by Institutions | 108.79% |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| SCOTT ROBERT A | 31.20 | - | 2,819 | 87,953 |
| Aggregate Net Quantity | 2,819 | |||
| Aggregate Net Value ($) | 87,953 | |||
| Aggregate Avg. Buy ($) | 31.20 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| SCOTT ROBERT A | Director | 23 Oct 2026 | Acquired (+) | 2,819 | 31.20 | 87,953 |
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |